Pathogen reduction with methylene blue does not have an impact on the clinical effectiveness of COVID-19 convalescent plasma (2023)

Peer-Reviewed Study · Romera Martínez I; Bueno Cabrera JL; Domingo-Morera JM; López Aguilar JC; Villegas Da Ros C; García Erce JA; Sáez Serrano I; Flores Ballester E; Maglio LA; Arbona Castaño C; Sola Lapeña C; Guerra Domínguez L (and co-authors) · February 3, 2023

Romera Martínez I et al., 2023-02-03: Ad hoc sub-study of the Spanish ConPlas-19 trial comparing 90 patients given methylene blue-treated convalescent plasma with 85 given amotosalen- or riboflavin-treated plasma: no evidence that methylene blue treatment worsened outcomes.

Our data suggest that MB-treated CCP does not provide a worse clinical outcome compared to the other PR methods for the treatment of COVID-19.

Abstract

Romera Martínez I et al., 2023-02-03: Ad hoc sub-study of the Spanish ConPlas-19 trial comparing 90 patients given methylene blue-treated convalescent plasma with 85 given amotosalen- or riboflavin-treated plasma: no evidence that methylene blue treatment worsened outcomes. Study type: prespecified/ad hoc sub-study of a randomised trial (ConPlas-19); N=175 inpatients with SARS-CoV-2 pneumonia (MB 90, riboflavin 60, amotosalen 25). Comparator: other pathogen-reduction methods. Result: respiratory worsening 5.6% with MB vs 10.6% with alternatives (p=0.220; RR 0.52, 95% CI 0.18-1.50). Funding: Instituto de Salud Carlos III COV20/00072. Conflicts not stated in retrieved abstract record. Bearing: safety-of-process finding, not efficacy of MB as a therapy. Study type: controlled study.